NCT05498610View on ClinicalTrials.gov

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

NNC0480 0389

"Participants will get 1 injections of NNC04800389. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"

DRUG

Semaglutide

"Participants will get 1 injections of semaglutide. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"

Trial Locations (1)

100730

Novo Nordisk Investigational Site, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY